TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Sponsor: Carl Allen · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 90 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,626,800

Rescue Site Savings

+$1,062,400

Unlock Full NCT04079179 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04079179 Rescue Dossier →